Vertebral Artery Rapamycin Targeted Eluting Stent System Approved by NMPA

On December 18, 2020, NMPA granted Innovative Approval to the Vertebral Artery Rapamycin Targeted Eluting Stent System produced by Microport. The single-sided grooving drug-coated stent of this product is designed to enhance targeted drug release and improve the efficiency of drug therapy. Thus, intracellular restenosis and stent thrombosis induced by cell proliferation can be alleviated.It provides more clinical treatment options for patients with symptomatic extracranial vertebral artery stenosis.

Link: https://www.nmpa.gov.cn/yaowen/ypjgyw/20201218153351197.html